Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

NEXR vs CMND: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CMND Wins Head-to-Head Institutional Verdict (3–0 across 6 Pillars · 8–0 Matrix Metrics)

CMND Overall Winner 6-Pillar Tally: NEXR 0 – 3 CMND (3 Tie) Matrix Metrics: NEXR 0 – 8 CMND

As of Nov 16, 2026, Clearmind Medicine Inc. Common Shares (CMND) is the stronger overall head-to-head candidate over NEXR (NEXR) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). NEXR carries a Unified Composite Score of 31.0/100 (SELL) at $1.38 (N/M Forward P/E, N/A operating margin), whereas CMND carries 49.8/100 (HOLD) at $4.18 (N/M Forward P/E, 0.0% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NEXR vs CMND
NEXR US Equity
NEXR
Institutional Equity
$1.38
-7.38% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 8.42β · 2730% Vol
Unified Composite Score
31.0 / 100 SELL
Tech 50.0 Fund 27.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 56
RSI-14: 55.6 · SMA20: $0.94 · SMA50: $1.16
CMND NASDAQ Head-to-Head Winner
Clearmind Medicine Inc. Common Shares
Pharmaceutical Preparations
$4.18
-7.67% 1D
Market Cap $2.3M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 3.87β · 58% Vol
Unified Composite Score
49.8 / 100 HOLD
Tech 40.0 Fund 48.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 35
RSI-14: 35.1 · SMA20: $5.62 · SMA50: $3.96

6-Pillar Scorecard Institutional Category Breakdown (NEXR 0 – 3 CMND)

Columns: Metric · NEXR · CMND
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale CMND
Revenue Growth (YoY) N/A +0.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A N/A
Market Cap N/A $2.3M
3. Profitability & Quality CMND
Gross Margin N/A N/A
Operating Margin N/A 0.0%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -107.0%
4. Balance Sheet & Cash Flow CMND
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $10M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NEXR (0) vs CMND (8)
Institutional Metric NEXR CMND Criterion Row Edge
Market Capitalization
Scale
N/A $2.3M Larger Scale CMND
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +0.0% Higher Growth CMND
Operating Margin (TTM)
Profitability
N/A 0.0% Higher Margin CMND
Net Profit Margin
Profitability
N/A 0.0% Higher Margin CMND
Return on Equity (ROE)
Capital Efficiency
N/A -107.0% Higher ROE CMND
52-Week Range Position
Momentum
23% ($0–$5) 58% ($0–$7) Stronger Trend CMND
Beta / 30D Volatility
Risk Regime
8.42β · 2730% Vol 3.87β · 58% Vol Lower Realized Risk CMND
Unified Institutional Score
Composite Signal
31.0 / 100 (SELL) 49.8 / 100 (HOLD) Higher Composite CMND
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A ($10M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NEXR +100.45 pp
NEXR: +67.27% · CMND: -33.18%
3M Horizon CMND +161.13 pp
NEXR: -47.73% · CMND: +113.4%
6M Horizon CMND +999.69 pp
NEXR: +0.73% · CMND: +1000.42%
1Y Horizon CMND +341.39 pp
NEXR: -39.21% · CMND: +302.18%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NEXR vs CMND. Trailing 12-month operating profitability (NEXR N/A vs CMND 0.0%) and valuation multiples (NEXR N/M vs CMND N/M Forward P/E) are benchmarked directly in Pillar 4 below.

NEXR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
CMND ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-107.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NEXR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NEXR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CMND UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CMND Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NEXR Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CMND Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ NEXR vs CMND Key Questions & Quantitative Answers

As of Nov 16, 2026, Clearmind Medicine Inc. Common Shares (CMND) is the stronger overall head-to-head candidate over NEXR (NEXR) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). NEXR carries a Unified Composite Score of 31.0/100 (SELL) at $1.38 (N/M Forward P/E, N/A operating margin), whereas CMND carries 49.8/100 (HOLD) at $4.18 (N/M Forward P/E, 0.0% operating margin). Technically, NEXR sits in a Neutral phase (RSI 55.6, UNCLASSIFIED options structure) and CMND sits in a Neutral phase (RSI 35.1, UNCLASSIFIED options structure).

CMND leads the Growth & Scale pillar: NEXR posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with CMND at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, NEXR generates N/A in USD-normalized revenue versus N/A for CMND. In operating R&D and SG&A reinvestment, NEXR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CMND.

NEXR and CMND trade at balanced relative valuation multiples. NEXR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CMND trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NEXR (N/A ROE) versus CMND (-107.0% ROE) capital efficiency.

In options market volatility and institutional positioning, NEXR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (8.42β · 2730% Vol realized risk). By comparison, CMND carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (3.87β · 58% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.